Recent Updates
Recently added Catalysts
IMCR Positive Sentiment Score: 70/100

Immunocore to present at the 22nd Annual Needham Virtual Healthcare Conference

Tuesday, April 11, 2023 2 min read
Key Takeaway: Immunocore Holdings Plc (Nasdaq: IMCR) announced its participation in the 22nd Annual Needham Virtual Healthcare Conference, scheduled for April 17, 2023. The presentation will highlight its development of T cell receptor bispecific immunotherapies aimed at treating various diseases. Notably, the company's product KIMMTRAK has received approvals for treating HLA-A*02:01-positive adult patients with certain forms of melanoma. The event will be webcast live from Immunocore's website.

Market Sentiment Analysis

POSITIVE FACTORS

  • Immunocore is making significant advancements in TCR bispecific immunotherapies.
  • The company is presenting at a prominent healthcare conference, showcasing its innovations.
  • Immunocore has a strong pipeline, including multiple clinical stage programs.

Full Press Release Details

Immunocore to present at the 22nd Annual Needham Virtual Healthcare Conference
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 11 April 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious diseases and autoimmune conditions, today announced that management will present at the 22nd Annual Needham Virtual Healthcare Conference.
The presentation is scheduled for Monday, April 17, 2023, at 3:45 p.m. Eastern Daylight Time (EDT).
The presentation will be webcast live and will be available in the ‘Investors’ section of Immunocore’s website at www.immunocore.com. Following the event, a replay of the presentation will be made available for a limited time.
Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune, and infectious disease. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including four clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. The Company’s most advanced oncology TCR therapeutic, KIMMTRAK has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.
Sébastien Desprez, Head of Communications
T: +44 (0) 7458030732
E: sebastien.desprez@immunocore.com
Follow on Twitter: @Immunocore
Consilium Strategic Communications (corporate and financial)
Mary-Jane Elliott/ Chris Welsh/Jessica Hodgson
T: +44 (0)203 709 5700
E: Immunocore@consilium-comms.com
Clayton Robertson, Head of Investor Relations
E: ir@immunocore.com

Tags

Frequently Asked Questions

What is Immunocore presenting at the Needham Conference?

Immunocore will present at the 22nd Annual Needham Virtual Healthcare Conference.

When is Immunocore's presentation scheduled?

The presentation is scheduled for April 17, 2023, at 3:45 p.m. EDT.

Where can I watch Immunocore's presentation?

The presentation will be webcast live on Immunocore’s website.

What type of therapies does Immunocore develop?

Immunocore develops TCR bispecific immunotherapies for various diseases.

What is KIMMTRAK used to treat?

KIMMTRAK is approved for unresectable or metastatic uveal melanoma.

Tags: IMCR Viatris Investor Conferences Healthcare Immunocore TCR bispecific immunotherapies healthcare conference KIMMTRAK
Last updated: Apr 11, 2023